PLATINOL Drug Patent Profile

Which patents cover Platinol, and what generic alternatives are available?

Platinol is a drug marketed by Hq Spclt Pharma and is included in one NDA.

The generic ingredient in PLATINOL is cisplatin. There are fourteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the cisplatin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Platinol

A generic version of PLATINOL was approved as cisplatin by PHARMACHEMIE BV on May 16^th, 2000.

Summary for PLATINOL

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	343
DailyMed Link:	PLATINOL at DailyMed

Recent Clinical Trials for PLATINOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Regeneron Pharmaceuticals	Phase 2
AstraZeneca	Phase 3
Wuhan Union Hospital, China	Phase 2

See all PLATINOL clinical trials

Pharmacology for PLATINOL

Drug Class

Platinum-based Drug

US Patents and Regulatory Information for PLATINOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hq Spclt Pharma	PLATINOL	cisplatin	INJECTABLE;INJECTION	018057-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Hq Spclt Pharma	PLATINOL-AQ	cisplatin	INJECTABLE;INJECTION	018057-003	Jul 18, 1984		DISCN	Yes	No

Expired US Patents for PLATINOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hq Spclt Pharma	PLATINOL	cisplatin	INJECTABLE;INJECTION	018057-001	Approved Prior to Jan 1, 1982
Hq Spclt Pharma	PLATINOL	cisplatin	INJECTABLE;INJECTION	018057-001	Approved Prior to Jan 1, 1982

International Patents for PLATINOL

See the table below for patents covering PLATINOL around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	149192
Australia	4383379
France	2427097
Norway	790313
Hungary	177557	PROCESS FOR PREPARING STABLE AEQUOUS STERILE SOLUTION OF CYS-PLATINIC/II/-DIAMINE-DICHLORIDE
South Africa	7900395

PLATINOL Market Analysis and Financial Projection Experimental

Platinum-Based Cancer Drugs: Market Dynamics and Financial Trajectory

Introduction

Platinum-based cancer drugs, such as Platinol (Cisplatin), have been a cornerstone in the treatment of various cancers for decades. This article delves into the market dynamics and financial trajectory of these drugs, highlighting key drivers, challenges, and future outlook.

Market Size and Growth

The global platinum-based cancer drug market is projected to grow significantly over the forecast period. By 2030, the market is expected to reach USD 1870 million, growing at a Compound Annual Growth Rate (CAGR) of 3% from 2023 to 2030. This growth is driven by increasing concerns over high cancer death rates and the rising awareness about platinum-based treatment therapies[1][4].

Market Drivers

Several factors are driving the growth of the platinum-based cancer drug market:

Increasing Cancer Prevalence

The rising number of new cancer cases globally is a significant driver. For instance, the National Cancer Institute estimates that new cases of cancer will continue to increase, particularly in regions like the U.K. and the U.S.[1][4].

Government and NGO Support

Government initiatives and aid from non-governmental organizations (NGOs) are promoting cancer care and treatment, which in turn boosts the demand for platinum-based drugs[1].

Research and Development

Continuous research and development aimed at enhancing the target concentration and efficacy of platinum-based drugs are expected to provide numerous opportunities in the market. Innovations such as new formulations and combination therapies are also contributing to market growth[1][3].

Regional Growth

North America holds the largest market share due to high cancer prevalence, recent FDA approvals, and significant investments in research and development. The Asia Pacific region is anticipated to expand at the highest CAGR due to rising disease prevalence, increased awareness, higher per capita income, and improvements in healthcare infrastructure[1][4].

Market Segmentation

The platinum-based cancer drug market is segmented by type, application, and distribution channel.

By Type

Cisplatin (Platinol) has historically held the largest share of the market and is expected to maintain its leadership position. Other types include Carboplatin, Oxaliplatin, and others. Each of these drugs has specific applications and side effect profiles[4].

By Application

These drugs are used in the treatment of various cancers, including lung, brain, and other solid tumors. The versatility of platinum-based drugs in treating different types of cancer contributes to their market demand[1].

By Distribution Channel

The distribution channels include hospitals, clinics, and retail pharmacies. The ease of access to these drugs through various distribution channels is crucial for their market growth[1].

Competitive Landscape

The market is competitive, with several key players involved in the development and commercialization of platinum-based drugs. Companies are focusing on enhancing drug formulations, such as developing oral formulations like Utidelone Capsule, which offers better bioavailability and patient compliance[3].

Challenges and Restraints

Despite the growth potential, there are several challenges facing the platinum-based cancer drug market:

Side Effects and Failure Rates

The side effects associated with platinum-based chemotherapy, such as nephrotoxicity and neurotoxicity, can limit the market growth. Additionally, the failure rates of these drugs in certain cases can also restrain market expansion[1].

Regulatory Hurdles

Stringent regulatory requirements and the need for FDA approvals can slow down the market growth. However, recent approvals and ongoing research are mitigating some of these challenges[1].

Financial Trajectory

The financial trajectory of the platinum-based cancer drug market is positive, driven by increasing demand and continuous innovation.

Investment in R&D

Significant investments in research and development are expected to drive the market forward. Companies are leveraging advanced technologies, such as synthetic biology, to develop new and improved drug formulations[1][3].

Regional Market Performance

North America and the Asia Pacific are expected to be key regions driving the financial growth of the market. The increasing number of patients, growing investments in R&D, and the establishment of advanced research centers are contributing factors[1][4].

Future Outlook

The future outlook for the platinum-based cancer drug market is promising, with several trends expected to shape the market:

Emerging Markets

The Asia Pacific region is expected to expand significantly due to rising disease prevalence and improvements in healthcare infrastructure. This presents a lucrative opportunity for market players[1][4].

New Formulations and Therapies

The development of new formulations, such as oral capsules and nano-injections, is expected to enhance patient compliance and treatment outcomes. Combination therapies involving platinum-based drugs are also on the horizon, offering new treatment options[3].

Regulatory Support

Government initiatives and regulatory support are crucial for the market's future growth. Recent FDA approvals and ongoing research indicate a favorable regulatory environment[1].

"According to the National Cancer Institute, new cases of cancer will continue to increase, particularly in regions like the U.K. and the U.S."[1]

Key Takeaways

• The global platinum-based cancer drug market is projected to reach USD 1870 million by 2030, growing at a CAGR of 3% from 2023 to 2030.
• North America holds the largest market share, while the Asia Pacific region is expected to grow at the highest CAGR.
• Cisplatin (Platinol) is the leading drug in this market segment.
• Increasing cancer prevalence, government support, and R&D investments are key drivers.
• Side effects and regulatory hurdles are significant challenges.
• New formulations and combination therapies are expected to drive future growth.

FAQs

Q: What is the projected market size of the platinum-based cancer drug market by 2030?

A: The global platinum-based cancer drug market is expected to reach USD 1870 million by 2030[1].

Q: Which region holds the largest market share in the platinum-based cancer drug market?

A: North America holds the largest market share in the platinum-based cancer drug market[1][4].

Q: What are the main types of platinum-based cancer drugs?

A: The main types include Cisplatin (Platinol), Carboplatin, Oxaliplatin, and others[4].

Q: What are the key drivers of the platinum-based cancer drug market?

A: Key drivers include increasing cancer prevalence, government and NGO support, and continuous research and development[1].

Q: What are the major challenges facing the platinum-based cancer drug market?

A: Major challenges include side effects associated with chemotherapy and regulatory hurdles[1].

Sources

1. Infinium Global Research, Global Platinum Based Cancer Drug Market Size, Share, Trends | IGR
2. Platinum Asset Management, Quarterly Report
3. Moomoo, AP00 Warning 63412-11P 1..1
4. BioSpace, Platinum-based Drugs Market: Cisplatin segment held the largest share of the market